Proton radiotherapy outcomes in pediatric ependymoma: A long-term meta-analysis (PROPEL)
Abstract
Objectives: To synthesize existing evidence on pencil-beam and passive-scattering proton therapy outcomes in pediatric intracranial ependymoma and to generate pooled estimates of five-year overall survival (OS), local control (LC), progression-free survival (PFS), and late toxicity profiles.
Materials and methods: We performed a random-effects meta-analysis (with fixed- and random-effects estimates converging when between-study heterogeneity was negligible) of eight retrospective single-center cohorts (2000-2025) encompassing 1100 children treated with 54-60 Gy(RBE) proton therapy. Primary endpoints were five-year OS, LC, and PFS. Secondary endpoints included growth hormone deficiency (GHD), hypothyroidism, radionecrosis, and secondary malignancies. Pooled proportions and 95 % confidence intervals (CIs) were calculated for each outcome. Between-study heterogeneity was assessed via Cochran's Q and I² statistics. Meta-regression evaluated the influence of surgical extent, proton dose, and delivery technique on oncologic endpoints.
Results: Five-year OS was 83.1 % (95 % CI 80.7-85.4 %), LC 84.9 % (95 % CI 82.7-87.2 %), and PFS 74.1 % (95 % CI 71.3-76.9 %), each with negligible heterogeneity (I² = 0 %). Late toxicities were modest: GHD in 21.3 % (95 % CI 18.8-23.8 %), hypothyroidism in 15.0 % (95 % CI 12.9-17.1 %), ototoxicity grade 2 or higher in 5 % (95 % CI 3.5-6.5 %), radionecrosis in 2.0 % (95 % CI 1.5-3.5 %), and secondary malignancy in 0.65 % (95 % CI 0.17-1.13 %).…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,100 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.